A novel CD38 inhibitor, which has excellent in vivo efficacy, favorable pharmacokinetics, and attractive safety profile, was reported for the treatment of mitochondrial myopathy
A novel CD38 inhibitor, which has excellent in vivo efficacy, favorable pharmacokinetics, and attractive safety profile, was reported for the treatment of mitochondrial myopathy
Cpyright © 2025 Nanjing Immunophage Biomedical Co.,Ltd
All Rights Reserved. 苏ICP备2022026466号-1 
苏公网安备 32011202000830号
Click here to learn more